Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.39 |
| ▸ | TUBB | P07437 | 3/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188912 | 0.85 | PTGS2 (0.42) | PTGS2EGFRKDR | |
| SCHEMBL617852 | 0.84 | PTGS2 (0.51) | PTGS2GAATUBB4ATUBBTUBA3C | |
| SCHEMBL617751 | 0.83 | POLB (0.55) | EGFRKDRTUBB4ATUBBTUBA3C | |
| SCHEMBL615932 | 0.82 | PTGS2 (0.52) | PTGS2FYNTUBB4ATUBBTUBA3C | |
| SCHEMBL616273 | 0.81 | PTGS2 (0.72) | PTGS2FYNTUBB4ATUBBTUBA3C | |
| SCHEMBL617522 | 0.81 | PTGS2 (0.43) | PTGS2GAAFYNTUBB4ATUBB | |
| SCHEMBL618456 | 0.80 | MAPK1 (0.52) | PTGS2EGFRKDRKDM4EALDH1A1 | |
| SCHEMBL616937 | 0.80 | PTGS2 (0.70) | PTGS2FYNTUBB4ATUBBTUBA3C | |
| SCHEMBL617838 | 0.80 | FYN (0.55) | PTGS2KDRGAAFYNTUBB4A | |
| SCHEMBL616176 | 0.80 | PTGS2 (0.54) | PTGS2TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1966172-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | PTGS2 3488/4885EGFR 257/4885KDR 58/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885EGFR 257/4885KDR 58/4885 |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885EGFR 257/4885KDR 58/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885EGFR 257/4885KDR 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.